title: Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
abstract: BACKGROUND
  The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/DOQItrade mark) has established guidelines for treatment of secondary hyperparathyroidism (HPT). The ability of cinacalcet HCl (Sensipartrade mark) treatment to improve achievement of target levels of parathyroid hormone (PTH), calcium, phosphorus, and calcium-phosphorus product (Ca x P) was investigated in subjects on dialysis with secondary HPT.
  
  
  METHODS
  Data were combined from three placebo-controlled, double-blind, 26-week studies with similar design that randomized 1136 subjects on dialysis to receive traditional therapy plus cinacalcet or placebo. Oral cinacalcet was titrated from 30 to 180 mg/day. Achievement of K/DOQI goals was determined for each treatment group overall and for subgroups defined by baseline intact PTH (iPTH) and Ca x P levels.
  
  
  RESULTS
  Cinacalcet-treated subjects were more likely to achieve a mean iPTH </=300 pg/mL (31.8 pmol/L) than were control subjects on traditional therapy (56% vs. 10%, P < 0.001). Cinacalcet-treated subjects were more likely to achieve concentrations of serum calcium within 8.4 to 9.5 mg/dL (2.10-2.37 mmol/L) and serum phosphorus within 3.5 to 5.5 mg/dL (1.13-1.78 mmol/L) than were control subjects (49% vs. 24% and 46% vs. 33%, P < 0.001 for each). Cinacalcet also improved achievement of Ca x P < 55 mg(2)/dL(2) (4.44 mmol(2)/L(2)) and concurrent achievement of Ca x P < 55 mg(2)/dL(2) (4.44 mmol(2)/L(2)) and iPTH </=300 pg/mL (31.8 pmol/L) (65% vs. 36% and 41% vs. 6%, P < 0.001 for each).
  
  
  CONCLUSIONS
  In subjects on dialysis with secondary HPT, cinacalcet facilitates achievement of the K/DOQI-recommended targets for PTH, calcium, phosphorus, and Ca x P.
authors.affiliation: Indiana University School of Medicine, Indianapolis, Indiana 46202, USA. smoe@iupui.edu
authors.forename: Sharon M
authors.initials: SM
authors.lastname: Moe
authors.forename: Glenn M
authors.initials: GM
authors.lastname: Chertow
authors.forename: Jack W
authors.initials: JW
authors.lastname: Coburn
authors.forename: L Darryl
authors.initials: LD
authors.lastname: Quarles
authors.forename: William G
authors.initials: WG
authors.lastname: Goodman
authors.forename: Geoffrey A
authors.initials: GA
authors.lastname: Block
authors.forename: Tilman B
authors.initials: TB
authors.lastname: Drüeke
authors.forename: John
authors.initials: J
authors.lastname: Cunningham
authors.forename: Donald J
authors.initials: DJ
authors.lastname: Sherrard
authors.forename: Laura C
authors.initials: LC
authors.lastname: McCary
authors.forename: Kurt A
authors.initials: KA
authors.lastname: Olson
authors.forename: Stewart A
authors.initials: SA
authors.lastname: Turner
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Martin
mesh_terms: D000328:Adult; D000368:Aged; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D002118:Calcium / Q000097:blood; D000069449:Cinacalcet; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000009:adverse effects / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood
chemical_list: D009281:Naphthalenes; D010281:Parathyroid Hormone; D010758:Phosphorus; D002118:Calcium; D000069449:Cinacalcet